Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7126 USD | +1.80% | -9.56% | -77.87% |
06-18 | Oppenheimer Downgrades Ovid Therapeutics to Market Perform | MT |
06-18 | B. Riley Adjusts Price Target on Ovid Therapeutics to $3 From $9, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-77.87% | 49.66M | |
+16.49% | 122B | |
+21.73% | 116B | |
+22.18% | 27.03B | |
-21.81% | 20.36B | |
-16.89% | 16.43B | |
-18.81% | 15.91B | |
-44.74% | 15.6B | |
+62.72% | 14.94B | |
+3.09% | 13.59B |
- Stock Market
- Equities
- OVID Stock
- News Ovid Therapeutics Inc.
- Citigroup Adjusts Price Target on Ovid Therapeutics to $1.20 From $3.50, Maintains Neutral Rating